The Korea Innovative Medicines Consortium (KIMCo) said Monday that it would conduct a joint investment project to help strengthen the Korean biopharmaceutical industry’s global competitiveness.
How are VC investors driven or impacted by barriers to entry, and/or the complexity of startups that spin out of university-based research, particularly within UC Berkeley?
